# EDGAR Filing Document

**Accession Number:** 0001848731
**File Stem:** 0001848731-26-000024
**Filing Date:** 2026-5
**Character Count:** 38319
**Document Hash:** 0e682535d2e3eb723a48bfbfac61bde4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001848731-26-000024.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001848731-26-000024

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260513

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Glass House Brands Inc.
- **CENTRAL INDEX KEY:** 0001848731
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56261
- **FILM NUMBER:** 26973551

**BUSINESS ADDRESS:**
- **STREET 1:** 3645 LONG BEACH BLVD
- **CITY:** LONG BEACH
- **STATE:** CA
- **ZIP:** 90807
- **BUSINESS PHONE:** 562-264-5078

**MAIL ADDRESS:**
- **STREET 1:** 3645 LONG BEACH BLVD
- **CITY:** LONG BEACH
- **STATE:** CA
- **ZIP:** 90807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mercer Park Brand Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210302

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May, 2026.

Commission File Number 000-56261

**<u>Glass House Brands Inc.</u>**

(Translation of registrant's name into English)

3645 Long Beach Blvd.

<u>Long Beach, California 90807</u>

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⌧

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| | **Glass House Brands Inc.** |
| Date: May 13, 2026 | /s/ Kyle Kazan |
|  | By: Kyle Kazan |
|  | Title: Chief Executive Officer |

---

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| <u>[99.1](glas2026q16-kerex991.htm)</u> | <u>[News Release, dated May 13, 2026](glas2026q16-kerex991.htm)</u> |

---

## Exhibit 99.1

**Exhibit 99.1**

**Glass House Brands Reports First Quarter 2026 Financial Results**

*-First quarter results include revenue of $40.5 million, average selling price of $171 per pound and biomass production of 152,000 pounds*

*-Company reiterates full year 2026 wholesale cannabis biomass production forecast of approximately 1,000,000 pounds and $95 per pound annual production cost target*

*-Company has submitted applications for DEA registration to fully operate medical business under Schedule III Classification*

*-Conference Call to be held today May 13, 2026, at 5:00 p.m. ET*

**LONG BEACH, CA and TORONTO, May 13, 2026** - Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., today reported financial results for the first quarter ended March 31, 2026.

**First Quarter 2026 Highlights**

(Unaudited results, unless otherwise stated, all results and dollar references are in U.S. dollars)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Revenue** was $40.5 million, compared to $44.8 million in Q1 last year and $38.9 million in the fourth quarter 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Gross Profit Margin** of 25%, compared to 45% in first quarter 2025 and 34% in fourth quarter 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted EBITDA**<sup>1</sup> was negative $(4.2) million, compared to positive $4.4 million in first quarter 2025 and $(3.3) million in fourth quarter 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Operating Cash Flow** of negative $(11.8) million, compared to $2.5 million in first quarter 2025 and negative $(3.7) million in fourth quarter 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Equivalent Dry Pound Production**<sup>2</sup> was 151,531 pounds, compared to 152,568 in first quarter 2025 and 159,131 in fourth quarter 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cost per Equivalent Dry Pound of Production**<sup>3</sup> of $175 per pound, compared to $108 per pound in first quarter 2025 and $129 per pound in fourth quarter 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash, Restricted Cash and Cash Equivalents balance** was $27.9 million at March 31, 2026 compared to $23.4 million at the end of fourth quarter 2025.

**Management Commentary**

"The recent rescheduling of medical cannabis represents a landmark event within our industry," said Kyle Kazan, Co-Founder, Chairman and CEO of Glass House. "The implications for Glass House are vast, including potential 280E tax relief and opening up interstate commerce or export to Europe, which would meaningfully increase our addressable market size and unlock greater profit and cash flow generation driven by more favorable pricing dynamics."

"Preparing for rescheduling has been a top priority for us this year and we have already made significant progress. We accelerated and completed the build-out of Greenhouse 2, and expect that this added capacity will contribute to sales in the second half of 2026. More recently, we registered with the DEA, permitting us to immediately operate medical operations under a Schedule III designation."

------

"Our quarterly results were in-line with previously announced preliminary results, reflecting a build-up of cultivation scale and transitory inflated cost of production. We have, and will continue to, make changes to ensure our future performance returns to the standards that we demand of ourselves."

"Importantly, we remain confident in our outlook for 2026 and have reiterated our guidance to produce approximately one million pounds of cannabis biomass this year, a record number for the Company, and anticipate an average selling price in the mid $180 per pound range. We expect quarterly cost of production to decline as the year progresses and believe our $95 cost of production target remains achievable on a quarterly basis within the second half of this year. We also continue to anticipate strong revenue growth in 2026, with revenue increasing progressively during the course of the year."

"Longer term, we retain the competitive advantages that have defined us, such as never having to pay the exorbitant energy bills of indoor peers nor having to rely on third-party water supply. It is these and other benefits of our operating model that have sustained us despite challenging California cannabis market conditions. The advantages will further separate the Company from our peers as we enter new markets and expand into new product categories with hemp."

**First Quarter 2026 Operational Highlights and Subsequent Events**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>University of California Berkeley and Glass House Collaboration Leads to State-Funded Research on Cannabis Crop Yields</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Glass House Brands Announces Accelerated 2026 Expansion Strategy</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Glass House Brands Announces Appointment of Alison Payne, Heineken USA Chief Marketing Officer, to its Board of Directors</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Glass House Brands Board of Directors Establishes Product Expansion Committee to Support New Product and Business Development</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Glass House Brands Announces California Retail Joint Venture with Vireo Growth</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Glass House Brands Announces Warrant Redemption Notice</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Glass House Brands Announces Application for DEA Registration of Certain Medical Operations</u>

**Q1 2026 Financial Results Discussion**

Revenues for first quarter 2025 were $40.5 million, ahead of guidance of $39 million and compared to $38.9 million in fourth quarter 2025 and $44.8 million in first quarter 2025. The decline is attributed to reduced wholesale prices and lower production volume.

The wholesale biomass segment revenue was $24.0 million, accounting for 59% of total revenue. Biomass production reached 151,531 pounds during Q1 2026, ahead of guidance of 138,000 pounds and compared to 152,568 in the prior year period.

First quarter 2025 retail segment revenue was $11.9 million, compared to $11.8 million the first quarter of last year and $11.9 million in fourth quarter 2025. Retail gross margin was 50% in the first quarter, compared to 47% in the fourth quarter.

Wholesale CPG segment revenues were $4.6 million, representing a 7% sequential increase and (2)% year-over-year decrease.

Consolidated gross profit for the first quarter was $10.0 million, compared to $20.1 million for Q1 last year and $13.2 million in fourth quarter 2025. Gross margin was 25%, compared to guidance of 29%, 45% in the prior year period and 34% in the fourth quarter of 2025. The declines stem from the lower average selling prices and higher production costs in the wholesale business.

------

Average selling price was $171 per pound, versus guidance of $167 and compared to $193 in the first quarter of 2025 as we are still operating amidst challenged California pricing conditions.

General and administrative expenses were $17.0 million for the first quarter of 2026, compared to $15.1 million last year and down 8% from $18.5 million in the fourth quarter.

Sales and marketing expenses were $0.5 million, compared to $0.7 million during the same period last year and $0.5 million in the prior quarter.

Professional fees were $2.9 million in Q1, compared to $2.9 million in Q4 2025 and $1.7 million in Q1 2025.

Depreciation and amortization in Q1 2026 were $4.0 million, compared to $4.0 million in Q4 2025 and $3.8 million in Q1 2025.

Adjusted EBITDA was negative $(4.2) million in Q1 2026, compared to positive $4.4 million in the first quarter 2025 and negative $(3.3) million in Q4 2025.

Operating cash flow was negative $(11.8) million, compared to positive $2.5 million in the year-ago period and negative $(3.7) million in Q4 2025.

As of March 31, 2026, the Company had $27.9 million of cash and restricted cash, compared to $23.4 million at the start of the first quarter. The Company spent $3.5 million in capex in the first quarter, which was mostly for Phase III expansion at Camarillo. The Company also paid $2.9 million in preferred stock dividend payments.

**Warrant Redemption Notice**

Subsequent to quarter end, the Company delivered a notice of redemption, dated April 28, 2026, with respect to the warrants (the "Warrants") outstanding under the warrant agency agreement, dated May 13, 2019, between the Company and Odyssey Trust Company, as amended (the "Warrant Agency Agreement").

There are currently 30,664,500 Warrants outstanding, each exercisable for one equity share (each, a "Share") of the Company at an exercise price of US$11.50 per Share. The outstanding Warrants will be redeemed on May 28, 2026 in accordance with Section 3.4 (1) of the Warrant Agency Agreement at a redemption price of .011826 Shares per Warrant (the "Redemption Shares"). If the Company had not taken any action, the outstanding Warrants would have expired on June 29, 2026.

For further information, please refer to the Company's <u>news release</u> dated April 28, 2026.

**At-The-Market Program**

The Company has entered into an equity distribution agreement (the "Equity Distribution Agreement") with ATB Cormark Capital Markets, pursuant to which, the Company may from time to time sell up to US$50 million of its subordinate voting shares, restricted voting shares and limited voting shares (collectively, the "Equity Shares") in an at-the-market distribution program (the "ATM Program"). The Company currently intends to use net proceeds of the ATM Program, if any, for cultivation expansion and/or general corporate purposes as well as potential acquisitions that may be identified in the future. The Company views its ATM programs as long term sources of potential capital to be accessed on an opportunistic basis, rather than servicing an immediate need.

Launch of the ATM Program is subject to the approval of CBOE Canada, the delivery of customary closing deliverables and the filing of a prospectus supplement to the Company's base shelf prospectus dated May 16, 2024.

------

Since the Equity Shares will be distributed at trading prices prevailing at the time of the sale, prices may vary between purchasers and during the period of distribution. The volume and timing of sales, if any, will be determined at the sole discretion of the Company's management and in accordance with the terms of the Equity Distribution Agreement.

Sales of Equity Shares, if any, under the ATM Program are anticipated to be made in transactions that are deemed to be "at-the-market distributions" as defined in National Instrument 44-102 Shelf Distributions, as sales made directly on CBOE Canada or any other recognized Canadian "marketplace" within the meaning of National Instrument 21-101 *Marketplace Operation*.

Financial results and analyses will be available on the Company's website on the 'Investors' and 'News & Events' drop-down menus (<u>www.glasshousebrands.com</u>) and SEDAR+ (<u>www.sedarplus.ca</u>).

Unaudited results, unless otherwise stated, all results are in U.S. dollars.

---

| | | | |
|:---|:---|:---|:---|
| **Net Income / Loss** | **Net Income / Loss** | **Net Income / Loss** | **Net Income / Loss** |
| (in thousands) | **Q1 2025** | **Q4 2025** | **Q1 2026** |
| Revenues, Net | $44818 | $38855 | $40515 |
| Cost of Goods Sold | 24753 | 25649 | 30499 |
| Gross Profit | 20065 | 13206 | 10016 |
| &nbsp;&nbsp;&nbsp;% of Net Revenue | 45% | 34% | 25% |
| Operating Expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and Administrative | 15083 | 18474 | 16950 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and Marketing | 687 | 476 | 529 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional Fees | 1668 | 2912 | 2865 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 3837 | 4028 | 4022 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment | 1900 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Operating Expenses | 23175 | 25890 | 24366 |
| Loss from Operations | (3110) | (12684) | (14350) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Expense | 2276 | 1044 | 1295 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) Loss on Change in Fair Value of Contingent Liabilities and Shares Payable | (95) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (Income) Expense, Net | 1789 | (1194) | (1697) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other (Income) Expense, Net | 3970 | (150) | (402) |
| Income Taxes | 2928 | 2966 | 3058 |
| **Net Loss** | $**(10008)** | $**(15500)** | $**(17006)** |

---

------

---

| | | | |
|:---|:---|:---|:---|
| **Adjusted EBITDA** | **Adjusted EBITDA** | **Adjusted EBITDA** | **Adjusted EBITDA** |
| (in thousands) | **Q1 2025** | **Q4 2025** | **Q1 2026** |
| **Net Loss (GAAP)** | $**(10008)** | $**(15500)** | $**(17006)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 3837 | 4028 | 4022 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest, Net | 1988 | 1044 | 1295 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income Tax Expense | 2928 | 2966 | 3058 |
| **EBITDA (Non-GAAP)** | **(1255)** | **(7462)** | **(8631)** |
| **Adjustments:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-Based Compensation | 2105 | 4274 | 4523 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights Expense | (37) | (22) | (5) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) Loss on Equity Method Investments | (40) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in Fair Value of Derivative Asset and Liability | 1733 | (27) | (409) |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment Expense for Intangible Assets | 1900 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in Fair Value of Contingent Liabilities and Shares Payable | (95) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on Extinguishment of Debt | 292 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Employee Retention Tax Credits | (210) | (2365) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-Recurring Asset Casualty Loss |  | 939 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-Recurring Legal and Professional Fees |  | 1357 | 349 |
| **Adjusted EBITDA (Non-GAAP)** | $**4393** | $**(3306)** | $**(4173)** |

---

------

---

| | | | |
|:---|:---|:---|:---|
| **Select Cash Flow Information** | **Select Cash Flow Information** | **Select Cash Flow Information** | **Select Cash Flow Information** |
| (in thousands) | **Q1 2025** | **Q4 2025** | **Q1 2026** |
| Net Loss | $(10008) | $(15500) | $(17006) |
| Depreciation and Amortization | 3837 | 4028 | 4022 |
| Share-Based Compensation | 2105 | 4274 | 4523 |
| Impairment Expense for Intangibles | 1900 |  |  |
| (Gain) Loss on Change in Fair Value of Contingent Liabilities and Shares Payable | (95) |  |  |
| Other | 2573 | 1963 | (1911) |
| &nbsp;&nbsp;**Cash From Net Loss** | **312** | **(5235)** | **(10372)** |
| Accounts Receivable | (1424) | 410 | (2096) |
| Income Taxes Receivable |  | 1081 | 25 |
| Prepaid Expenses and Other Current Assets | 1086 | (412) | 1455 |
| Inventory | (1430) | (6851) | (5310) |
| Other Assets | 2062 | 134 | (14) |
| Accounts Payable and Accrued Liabilities | (587) | 7918 | 1855 |
| Income Taxes Payable | 27 | (2408) |  |
| Other | 2425 | 1662 | 2702 |
| &nbsp;&nbsp;**Working Capital Impact** | **2159** | **1534** | **(1383)** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Operating Activities Cash Flow** | **2471** | **(3701)** | **(11755)** |
| Purchases of Property and Equipment | (6695) | (2400) | (3546) |
| Other |  | 222 | 800 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Investing Activities Cash Flow** | **(6695)** | **(2178)** | **(2746)** |
| Proceeds from the Issuance of At-the-Money Shares |  | 2182 | 22302 |
| Proceeds from the Issuance of Notes Payable and Preferred Shares, Net of Redemption of Preferred Shares | 49140 |  | (250) |
| Payments on Notes Payable, Third Parties and Related Parties | (42068) | (238) | (10) |
| Distributions to Preferred Shareholders | (1938) | (2493) | (2888) |
| Other | (218) | 7 | (76) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Financing Activities Cash Flow** | **4916** | **(542)** | **19078** |
| Net Increase (Decrease) in Cash, Restricted Cash and Cash Equivalents | 692 | (6421) | 4577 |
| Cash, Restricted Cash and Cash Equivalents, Beginning of Period | 36923 | 29771 | 23350 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Cash, Restricted Cash and Cash Equivalents, End of Period** | $**37615** | $**23350** | $**27927** |

---

------

---

| | | | |
|:---|:---|:---|:---|
| **Select Balance Sheet Information** | **Select Balance Sheet Information** | **Select Balance Sheet Information** | **Select Balance Sheet Information** |
| (in thousands) | **Q1 2025** | **Q4 2025** | **Q1 2026** |
| Cash and Restricted Cash | $34615 | $19850 | $24427 |
| Accounts Receivable, Net | 6712 | 4417 | 6441 |
| Income Taxes Receivable | 1929 | 791 | 766 |
| Prepaid Expenses and Other Current Assets | 9608 | 15664 | 11181 |
| Inventory | 15682 | 26227 | 31537 |
| Notes Receivable |  | 800 |  |
| &nbsp;&nbsp;**Total Current Assets** | **68546** | **67749** | **74352** |
| Operating and Finance Lease Right-of-Use Assets, Net | 10188 | 5911 | 5961 |
| Long Term Investments | 2381 |  |  |
| Property, Plant and Equipment, Net | 212789 | 228760 | 229479 |
| Intangible Assets, Net | 12120 | 11577 | 11626 |
| Restricted Cash, Net of Current Portion | 3000 | 3500 | 3500 |
| Other Assets | 2566 | 1060 | 435 |
| &nbsp;&nbsp;**TOTAL ASSETS** | $**311590** | $**318557** | $**325353** |
| Accounts Payable and Accrued Liabilities | $30708 | $35970 | $38067 |
| Income Taxes Payable | 2435 |  |  |
| Shares Payable | 2485 |  |  |
| Current Portion of Operating and Finance Lease Liabilities | 2344 | 1952 | 2102 |
| Current Portion of Notes Payable |  | 37 | 38 |
| &nbsp;&nbsp;**Total Current Liabilities** | **37972** | **37959** | **40207** |
| Operating and Finance Lease Liabilities, Net of Current Portion | 8001 | 3954 | 3842 |
| Other Non-Current Liabilities | 25259 | 33413 | 36037 |
| Notes Payable, Net of Current Portion | 65797 | 68629 | 67819 |
| &nbsp;&nbsp;**TOTAL LIABILITIES** | **137029** | **143955** | **147905** |
| Preferred Equity Series B, C, D and E | 89002 | 92500 | 92500 |
| Additional Paid-In Capital, Accumulated Deficit and Non-Controlling Interest | 85559 | 82102 | 84948 |
| &nbsp;&nbsp;**TOTAL MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY** | **174561** | **174602** | **177448** |
| &nbsp;&nbsp;**TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY** | $**311590** | $**318557** | $**325353** |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Notes Payable and Preferred Equity** | **Notes Payable and Preferred Equity** | **Notes Payable and Preferred Equity** | **Notes Payable and Preferred Equity** | **Notes Payable and Preferred Equity** |
| (in thousands) | **Q3 2025** | **Q4 2025** | **Q1 2026** | **Comments** |
| **Notes Payable** |  |  |  |  |
| &nbsp;&nbsp;**Secured Credit Facility** | $50000 | $50000 | $50000 | Maturity is 2/28/30 |
| &nbsp;&nbsp;**2025 Lompoc Term Loan** | 2997 | 2990 | 2980 | Maturity is 8/4/35 |
| &nbsp;&nbsp;**Greenhouse 2 Equipment Supplier Financing** |  |  | 1120 |  |
| &nbsp;&nbsp;&nbsp;Series A | 11895 | 11895 | 10950 | 8% semi annual interest, cash or shares, higher of 10 day VWAP 5 trading days prior to pay date or $4.08, Maturity 4/15/27 |
| &nbsp;&nbsp;&nbsp;Series B | 4111 | 4111 | 3785 | 8% semi annual interest, cash or shares, lower of 10 day VWAP 5 trading days prior to pay date or $10.00, Maturity 4/15/27 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Plus Convertible Debt** | **16006** | **16006** | **14735** |  |
| &nbsp;&nbsp;&nbsp;Other | (153) | (330) | (978) | Mostly original issue discount |
| &nbsp;&nbsp;&nbsp;&nbsp;**Notes Payable Total** | $**68850** | $**68666** | $**67857** |  |
| **Preferred Equity** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Series D | 15000 | 15000 | 15000 | Currently at 15% dividend with 15% cash payment until 8/24/28 when it increases to 20% dividend with 20% cash payment |
| &nbsp;&nbsp;&nbsp;Series E | 77500 | 77500 | 77500 | 12% dividend with 12% cash payment |
| &nbsp;&nbsp;&nbsp;&nbsp;**Preferred Equity Total** | $**92500** | $**92500** | $**92500** |  |
| **Cash Payments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Debt Amortization | $597 | $239 | $10 |  |
| &nbsp;&nbsp;&nbsp;Cash Interest | 1222 | 1226 | (1314) | 8.58% interest rate on the Senior Secured Credit Facility, entered into on 2/28/25 and 8.5% interest rate on the 2025 Lompoc Term Loan, entered into on 8/4/25 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Debt Service** | **1819** | **1465** | **(1304)** |  |
| &nbsp;&nbsp;&nbsp;Series D | 563 | 563 | 563 | 15% annual rate until 8/24/28 when it increases to 20% |
| &nbsp;&nbsp;&nbsp;Series E | 1898 | 2358 | 2325 | 12% annual rate |
| &nbsp;&nbsp;&nbsp;&nbsp;**Preferred Equity Dividends** | **2461** | **2921** | **2888** |  |
| &nbsp;&nbsp;**Total Debt Service and Dividends** | $**4280** | $**4386** | $**1584** |  |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Equity Table** | **Equity Table** | **Equity Table** | **Equity Table** | **Equity Table** |
| (in thousands, except share price) | **Q1 2026** | **Q4 2025** | **Change** | **Comments** |
| **Total Equity and Exchangeable Shares&nbsp;&nbsp;&nbsp;&nbsp;** | 84663 | 81729 | 2934 | Shares issued in connection with At-the-Market program and exercise of RSUs, ISOs, and warrants |
| **Warrants** |  |  |  |  |
| Series D | 2770 | 2770 |  | Exercise price of $6.00 with an expiration date of August 2028 |
| Series C | 1000 | 1000 |  | Exercise price of $5.00 with an expiration date of August 2027 |
| Series B | 8407 | 8787 | (380) | Exercise price of $5.00 with an expiration date of August 2027 |
| SPAC | 30665 | 30665 |  | Exercise price of $11.50 with an expiration date of June 2026 |
| &nbsp;&nbsp;**Total Warrants** | **42842** | **43222** | **(380)** |  |
| Stock Options | 22 | 179 | (157) | Weighted average exercise price of $3.08 which expire in June 2026 |
| RSUs | 4756 | 5327 | (571) | Up to 3-year vesting through 2028 |
| &nbsp;&nbsp;**Total** | **4778** | **5506** | **(728)** |  |
| Share Price at Quarter End&nbsp;&nbsp;&nbsp;&nbsp; | $8.15 | $8.75 | $(0.60) |  |
| **Convertible Debentures** |  |  |  |  |
| Series A | $10950 | $11895 | $(945) | 8% semi annual interest, cash or shares, higher of 10 day VWAP 5 trading days prior to pay date or $4.08, Maturity 4/15/27 |
| Series B | 3785 | 4111 | (326) | 8% semi annual interest, cash or shares, lower of 10 day VWAP 5 trading days prior to pay date or $10.00, Maturity 4/15/27 |
| &nbsp;&nbsp;**Total Convertible Debentures** | $**14735** | $**16006** | $**(1271)** |  |
| &nbsp;&nbsp;&nbsp;Number of Shares if Converted Assuming Share Price at Quarter End&nbsp;&nbsp;&nbsp;&nbsp; | 1981 | 1829 | 152 |  |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Revenue** |
| (in thousands) | **Q3 2024** | **Q4 2024** | **Q1 2025** | **Q2 2025** | **Q3 2025** | **Q4 2025** | **Q1 2026** | **FY 2024** | **FY 2025** |
| Retail (B2C) | $11214 | $11796 | $11788 | $12262 | $12255 | $11938 | $11905 | $43816 | $48243 |
| Wholesale CPG (B2B) | 4777 | 4987 | 4747 | 5483 | 4958 | 4320 | 4637 | 17996 | 19508 |
| Wholesale Biomass (B2B) | 47830 | 36256 | 28283 | 42122 | 21231 | 22597 | 23973 | 139086 | 114233 |
| &nbsp;&nbsp;**Total** | $**63821** | $**53039** | $**44818** | $**59867** | $**38444** | $**38855** | $**40515** | $**200898** | $**181984** |
| **Sequential % Change&nbsp;&nbsp;&nbsp;&nbsp;** |  |  |  |  |  |  |  |  |  |
| Retail (B2C) | 3% | 5% | —% | 4% | —% | (3)% | —% |  |  |
| Wholesale CPG (B2B) | 20% | 4% | (5)% | 16% | (10)% | (13)% | 7% |  |  |
| Wholesale Biomass (B2B) | 22% | (24)% | (22)% | 49% | (50)% | 6% | 6% |  |  |
| &nbsp;&nbsp;**Total** | 18% | (17)% | (15)% | 34% | (36)% | 1% | 4% |  |  |
| **% Change to Prior Year** |  |  |  |  |  |  |  |  |  |
| Retail (B2C) | 11% | 23% | 19% | 13% | 9% | 1% | 1% | 12% | 10% |
| Wholesale CPG (B2B) | 11% | 22% | 12% | 38% | 4% | (13)% | (2)% | 12% | 8% |
| Wholesale Biomass (B2B) | 41% | 36% | 78% | 8% | (56)% | (38)% | (15)% | 32% | (18)% |
| &nbsp;&nbsp;**Total** | 32% | 31% | 49% | 11% | (40)% | (27)% | (10)% | 25% | (9)% |

---

------

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Gross Profit** | **Gross Profit** | **Gross Profit** | **Gross Profit** | **Gross Profit** | **Gross Profit** | **Gross Profit** | **Gross Profit** | **Gross Profit** | **Gross Profit** |
| (in thousands) | **Q3 2024** | **Q4 2024** | **Q1 2025** | **Q2 2025** | **Q3 2025** | **Q4 2025** | **Q1 2026** | **FY 2024** | **FY 2025** |
| Retail (B2C) | $4952 | $5396 | $5653 | $5861 | $6166 | $5621 | $5965 | $20763 | $23301 |
| Wholesale CPG (B2B) | 1398 | 1168 | 1221 | 1949 | 1477 | 818 | 1449 | 4517 | 5465 |
| Wholesale Biomass (B2B) | 27092 | 16187 | 13191 | 24121 | 4115 | 6767 | 2602 | 72113 | 48194 |
| &nbsp;&nbsp;**Total** | $**33442** | $**22751** | $**20065** | $**31931** | $**11758** | $**13206** | $**10016** | $**97393** | $**76960** |
| **% of Revenue** |  |  |  |  |  |  |  |  |  |
| Retail (B2C) | 44% | 46% | 48% | 48% | 50% | 47% | 50% | 47% | 48% |
| Wholesale CPG (B2B) | 29% | 23% | 26% | 36% | 30% | 19% | 31% | 25% | 28% |
| Wholesale Biomass (B2B) | 57% | 45% | 47% | 57% | 19% | 30% | 11% | 52% | 42% |
| &nbsp;&nbsp;**Total** | 52% | 43% | 45% | 53% | 31% | 34% | 25% | 48% | 42% |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Wholesale Biomass Production and Cost per Pound** | **Wholesale Biomass Production and Cost per Pound** | **Wholesale Biomass Production and Cost per Pound** | **Wholesale Biomass Production and Cost per Pound** | **Wholesale Biomass Production and Cost per Pound** | **Wholesale Biomass Production and Cost per Pound** | **Wholesale Biomass Production and Cost per Pound** | **Wholesale Biomass Production and Cost per Pound** | **Wholesale Biomass Production and Cost per Pound** | **Wholesale Biomass Production and Cost per Pound** |
| | **Q3 2024** | **Q4 2024** | **Q1 2025** | **Q2 2025** | **Q3 2025** | **Q4 2025** | **Q1 2026** | **FY 2024** | **FY 2025** |
| Equivalent Dry Pounds of Production | 232295 | 165074 | 152568 | 230748 | 123986 | 159131 | 151531 | 608478 | 666433 |
| % Change to Prior Year | 128% | 60% | 149% | 54% | (47)% | (4)% | (1)% | 71% | 10% |
| Cost per Equivalent Dry Pounds of Production | $103 | $110 | $108 | $91 | $128 | $129 | $175 | $123 | $111 |
| % Change to Prior Year | (13)% | (9)% | (41)% | (39)% | 24% | 17% | 62% | (10)% | (10)% |
| Ending Operational Canopy Licensed (000 sq. ft) | 1525 | 1525 | 1525 | 1525 | 1525 | 1708 | 1708 | 1525 | 1708 |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Wholesale Biomass Sold and Average Selling Price per Pound** | **Wholesale Biomass Sold and Average Selling Price per Pound** | **Wholesale Biomass Sold and Average Selling Price per Pound** | **Wholesale Biomass Sold and Average Selling Price per Pound** | **Wholesale Biomass Sold and Average Selling Price per Pound** | **Wholesale Biomass Sold and Average Selling Price per Pound** | **Wholesale Biomass Sold and Average Selling Price per Pound** | **Wholesale Biomass Sold and Average Selling Price per Pound** | **Wholesale Biomass Sold and Average Selling Price per Pound** | **Wholesale Biomass Sold and Average Selling Price per Pound** |
| | **Q3 2024** | **Q4 2024** | **Q1 2025** | **Q2 2025** | **Q3 2025** | **Q4 2025** | **Q1 2026** | **FY 2024** | **FY 2025** |
| Equivalent Dry Pounds Sold | 209175 | 164660 | 146555 | 204015 | 137026 | 154972 | 140421 | 568133 | 642568 |
| % Change to Prior Year | 108% | 68% | 160% | 48% | (34)% | (6)% | (4)% | 68% | 13% |
| Equivalent Dry Pounds Sold Average Selling Price | $229 | $220 | $193 | $206 | $155 | $146 | $171 | $245 | $177 |
| % Change to Prior Year | (32)% | (19)% | (32)% | (27)% | (32)% | (34)% | (11)% | (21)% | (28)% |

---

Equivalent Dry Pounds Average Selling Price excludes the impact of cultivation tax.

**Conference Call**

The Company will host a conference call to discuss the results today, May 13, 2026, at 5:00 p.m. Eastern Time.

---

| | |
|:---|:---|
| Webcast and Replay: | Register Here |
| Dial-In Number: | 1-800-715-9871 or 1-646-307-1963 |
| Conference ID: | 1950615# |

---

*(replay available for approximately 30 days)*

In addition, content related to the earnings call including a transcript and audio recording of the call, as well as the Company's financial statements and management's discussion and analysis of financial condition and results of operations for the period (upon completion), will be posted to the Company's website and can be found <u>here</u>. Content from previous reporting periods is also available.

------

**Non-GAAP Financial Measures**

Glass House defines EBITDA as Net Loss (GAAP) adjusted for interest and financing costs, income taxes, depreciation, and amortization. Adjusted EBITDA is defined as EBITDA excluding share-based compensation, stock appreciation rights expense, change in equity method investments, change in fair value of derivative instruments, impairment expense for goodwill and intangible assets, change in fair value of contingent liabilities and shares payable, loss on extinguishment of debt, employee retention tax credits, non-recurring casualty loss, non-recurring legal and professional fees and certain debt-related fees.

EBITDA and Adjusted EBITDA are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. Such supplemental non-GAAP financial measures are not standardized financial measures under U.S. GAAP used to prepare the Company's financial statements and might not be comparable to similar financial measures disclosed by other companies and, thus, should only be considered in conjunction with the GAAP financial measures presented herein.

The Company has provided tables above that provide a reconciliation of the Company's Net Loss (GAAP) to Adjusted EBITDA for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 and three months ended December 31, 2025.

Footnotes and Sources:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.EBITDA and Adjusted EBITDA are non-GAAP financial measures that are not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Please see "Non-GAAP Financial Measures" herein for further information and for a reconciliation of such non-GAAP measures to the closest GAAP measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Equivalent Dry Pound Production includes all dry production (flower, smalls and trim) plus equivalent dry weight for wet weight and fresh frozen not converted into dry weight by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Cost per Equivalent Dry Pound of Production, is the application of a subset of Costs of Goods Sold for cannabis biomass production (including all expenses from nursery and cultivation to curing and trimming - the point at which product is ready for sales as wholesale cannabis or to be transferred to CPG) applied to the Company's metric of dry production which includes all dry production (flower, smalls and trim) plus equivalent dry weight for wet weight and fresh frozen that is not converted into dry goods by the Company.

**About Glass House Brands**

<u>Glass House</u> is one of the fastest-growing, vertically integrated cannabis companies in the U.S., with a dedicated focus on the California market and building leading, lasting brands to serve consumers across all segments. Whether it be through its portfolio of brands, which includes <u>Glass House Farms</u>, <u>PLUS Products</u>, <u>Allswell</u> and Mama Sue Wellness or its network of retail dispensaries throughout the state of California, which includes <u>The Farmacy</u>, <u>Natural Healing Center</u> and <u>The Pottery</u>, Glass House is committed to realizing its vision of excellence: outstanding cannabis products, produced sustainably, for the benefit of all. For more information and company updates, visit <u>www.glasshousebrands.com/</u> and <u>https://ir.glasshousebrands.com/contact/email-alerts/</u>.

------

**Forward Looking Statements**

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or Glass House's future performance or financial results. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include, without limitation, statements regarding the completion of the proposed joint venture with Vireo and the anticipated benefits thereof . All forward-looking statements, including those herein, are qualified by this cautionary statement. Although Glass House believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. Accordingly, readers should not place undue reliance on forward-looking statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information, including those risks disclosed in the Glass House's Annual Information Form available on SEDAR+ at <u>www.sedarplus.ca</u> and in Glass House's Form 40-F available on EDGAR at <u>www.sec.gov</u>. For more information on Glass House, investors are encouraged to review Glass House's public filings on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The forward-looking statements and financial outlooks contained in this news release speak only as of the date of this news release or as of the date or dates specified in such statements. Glass House disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

**For further information, please contact:**

Glass House Brands Inc.

Jon DeCourcey, Vice President of Investor Relations

T: (781) 724-6869

E: <u>ir@glasshousebrands.com</u>

**Investor Relations Contact:** 

KCSA Strategic Communications

Phil Carlson

T: 212-896-1233

E: <u>GlassHouseIR@kcsa.com</u>

<br>